Claims
| Claim | Type | Assessment | Score | Review checks | References |
|---|---|---|---|---|---|
| In a 711-participant randomized phase 2b trial of heart failure with preserved or mildly reduced ejection fraction, 48 weeks of mitiperstat did not improve symptoms, six-minute walk distance, or secondary endpoints versus placebo, although safety was generally similar. | QUANTITATIVE | Supported | 0.9908 | 1 of 4 | 120 |